FASD is caused by alcohol exposure during pregnancy, but some pregnancies are higher risk than others and not all babies exposed to alcohol will develop symptoms. The UofL researchers believe that understanding what genes might increase that risk could lead to better therapeutics and help mothers make safer, more informed choices.��

“This condition can be harmful to both mom and baby,” said Ben Lovely, the study’s principal investigator and an assistant professor of biochemistry and molecular genetics in the . “Our goal is to help both by gaining insight into not just the surface-level risk factors, but also the genetic risk factors that haven’t really been explored.”

Symptoms of FASD vary, but can include problems with behavior, learning and physical development, including craniofacial malformations, such as a thin upper lip or small eye openings. According to the U.S. , one in 20, or 5% of school-aged children in the U.S. may be affected.

For mothers, Lovely said, it may be more complicated than just avoiding alcohol during pregnancy. The most sensitive window for FASD exposure is before many women even know they’re pregnant, and .

“Part of this is removing the stigma so we can talk about these things and find solutions that prevent or help mitigate the risks and effects of FASD,” Lovely said. “And the good news is, there may be some ways to do that.”

To explore genetic risk factors of FASD, researchers are looking to an unlikely source: zebrafish, which share 82% of the same genes as humans. Early studies have shown there may be some relatively simple ways to protect against FASD, such as by tweaking the formula of prenatal vitamins to lessen risk or developing therapeutics that address the birth defects that do happen.

“FASD is a complicated issue, and we need to address it from many angles,” Lovely said. “This isn’t as simple as saying ‘don’t drink.’ We need to develop more ways to help both mom and baby stay safe.”��

Arsenic is highly poisonous and occurs naturally in some rocks and soil. As a result, of exposure is drinking contaminated water, particularly ground water from private wells. More than get their water from private wells, including many in areas of Kentucky that may be contaminated from previous coal mining.��

“What people don’t realize is that private wells and even public water supplies serving smaller numbers of people are not regulated,” said , a UofL researcher who’s been studying arsenic’s role in cancer for more than 25 years. “People using private wells for their water are on their own to test for toxic chemicals.”��

Chronic exposure to low doses of arsenic, as from drinking water, can cause a host of serious health concerns, including cardiovascular disease, diabetes and several cancers, including skin, lung and bladder cancer. In high doses, arsenic can also be fatal.��

States and collaborator, , backed by two new grants from the National Institutes of Health and American Cancer Society totaling $3.6 million, are working to discover what specifically about arsenic exposure can cause and accelerate the development of those conditions. Understanding this cause and effect could help researchers and public health officials find ways to keep people safe and healthy.

States and Banerjee believe it may all come down to how arsenic binds with proteins that help the body regulate the expression of genes. When gene expression isn’t properly regulated, your cells can begin to behave abnormally, mutating and multiplying out of control and not dying when they should. In other words, they become cancer cells.��

Many proteins need zinc to do their jobs properly. When arsenic binds with these proteins instead, it takes the place zinc would normally fill. This disables these regulatory proteins and accelerates dysregulation.

Even worse, Banerjee said, is that there’s significant overlap between the communities who drink potentially contaminated well water and those who are more likely to have a zinc deficiency. If the body doesn’t have enough zinc to bind with the regulatory proteins in the first place, it can increase your risk of some of the same health concerns as arsenic exposure — including heart disease and cancer. An of the global population is zinc deficient.��

“It’s a double whammy,” said Banerjee, an assistant professor of pharmacology. “The populations we’re talking about are largely impoverished and rural, who are already more likely to be zinc deficient because they don’t have access to healthy, nutritious foods. So, you have a lack of zinc in the diet exacerbated by arsenic preventing what zinc they have from doing its job in the body.”��

There isn’t currently any medication that treats chronic arsenic exposure. However, Banerjee said, there may be a simple, over-the-counter solution — if the problem is a lack of zinc, it may be treatable with a zinc supplement. His research has shown zinc supplementation can mitigate or even regress some of the worse effects of arsenic exposure.��

“Zinc is over-the-counter, which makes it cheaper and readily accessible,” Banerjee said. “But I don’t think a lot of people are even aware of the potential danger of well water or what it can cause. We really hope this work can help those people.”

Suspended in a pediatric therapy harness, the boy’s feet moved across the treadmill. Each foot strike represented new hope for kids living with neurological conditions – to regain motor function, improve trunk control and even take steps on their own.������

That technology, invented by UofL researchers, is helping patients thanks to UofL’s unique suite of programs aimed at moving biomedical research from lab to market as products that can save and improve lives. Now, via a new partnership called the MidSouth Hub, UofL is offering its expertise to researchers across the four-state region of Kentucky, Virginia, Mississippi and Tennessee.����

“Seeing how the technology we’d worked so hard to support could impact that boy’s life was one of the proudest moments of my career,” said Jessica Sharon, senior director of innovation programs and new ventures at UofL. “That’s when I knew we were building something special here at UofL. With the MidSouth Hub, we can expand that impact and ensure even more potentially life-changing technologies make it out of universities and help patients.”��

PROOF OF CONCEPT��

UofL’s focus on innovation begins with the belief that good ideas shouldn’t stay in the lab — they belong out in the world, where they can make a positive impact as new diagnostics, treatments and therapeutics. To that end, the university has spent the past decade aggressively growing its support for biomedical innovation, helping researchers develop, test and refine their ideas before launch.��

UofL secured its first biomedical product innovation grant, the Wallace H. Coulter Translational Partnership, in 2011. Building on that success, UofL landed two more programs a few years later: Kentucky’s first NSF Innovation Corps (I-Corps) site and NIH Research Evaluation and Commercialization Hub (REACH), led by now retired professor, Paula Bates.����

Those were quickly followed by another award, then another, then another, and today, UofL holds a robust suite of programs unique from its peers across the country.�� With each new round of funding UofL forged�� new partnerships that expanded the impact first across the Commonwealth, and now, to the four-state region. The result is the MidSouth Hub, a multi-institution partnership led by Vanderbilt University, with UofL providing its original programming and leading efforts in Kentucky.��

“UofL has developed strategies that can help anyone to create healthcare solutions, whether you are a professor at a large university or a student at a technical college,” said Matt McMahon, Director of the NIH’s SEED (Small business ����ֱ�� and Entrepreneurial Development) Office, which supports REACH. UofL is the only university to succeed in all three rounds of REACH funding.��

“And in the end,” he said, “it’s patients and communities that benefit. We’re very excited to see UofL offer their leadership and expertise in scaling their approach across a broader part of the country.”��

That approach is key to developing technologies like the pediatric therapy harness, which provides partial body weight support as therapists help the kids move their feet over the treadmill. The idea is to slowly and safely turn on muscles and gain control. Designed by researchers Andrea Behrman and Tommy Roussel, that technology has since been licensed and units are in-place or on their way to facilities in Pennsylvania, Texas and New York, as well as Kentucky.��

“I don’t know a university that supports faculty more for innovation and biomedical design than UofL,” said Behrman, a professor of neurological surgery and director of the Kosair for Kids Center for Pediatric NeuroRecovery. “It’s a massive help in moving good ideas down the path, and getting them out where they can actually help patients.”��

THE RIGHT STUFF��

When it comes to good ideas, UofL has plenty to choose from. A Carnegie Research-1 university with a robust academic medical center and affiliated health system, UofL’s clinicians and researchers work to discover, invent, test and implement cutting-edge medical innovations that ultimately are commercialized.����

“This kind of direct impact just isn’t possible without those ingredients,” said Jon Klein, UofL’s interim executive vice president of research and innovation and vice dean for research at its School of Medicine. “That intersection of medicine, research and our suite of innovation programs — that mix is driving positive patient outcomes here and beyond.”��

Those positive outcomes cover a range of potentially devastating diagnoses. Take the�� cancer-fighting technology invented by researchers Geoffrey Clark, Joe Burlison and John Trent, which works by targeting the RAS protein. When mutated, RAS turns into a stuck accelerator pedal, with cells suddenly growing very fast and penetrating other tissue, just like a tumor cell.������

Stopping that process has long been considered a ‘holy grail’ that could shut down at least a third of human tumors. Thanks in part to support from UofL’s innovation programs, that technology is now in development with Qualigen Therapeutics, Inc., a publicly traded California-based biomedical company, and moving down the long pathway to FDA approval.����

“UofL is in a unique position to develop technologies like this because you not only have actual clinicians and cutting-edge research, but programs to assist industry partners to drive the resulting innovations to market,” said Michael Poirier, the company’s Chairman and CEO. “We look forward to continuing work with UofL and to advancing these important clinical technologies with the goal of developing an effective treatment for this unmet need.”��

READY TO LAUNCH��

Over the past decade, UofL’s I-Corps and REACH programs have supported hundreds of innovators, dozens of new products and licensing agreements, millions in follow-on funding and the launch of at least 16 new companies.��

One of those companies is led by School of Medicine researcher Matthew Neal, who participated in UofL’s Economic Development Administration-backed PRePARE program for developing pandemic-related technologies, along with the I-Corps site before going on to the prestigious national NSF program to develop his VR technology for patients with hearing deficiencies.��

Neal’s technology aims to help patients program their hearing aids and test out different models in realistic virtual environments, such as a noisy restaurant, all without leaving the comfort of the clinical setting.��

That led to a startup, Immersive Hearing Technologies, which Neal co-founded with former university entrepreneur-in-residence, Jeff Cummins. Together, they’ve already secured non-dilutive follow-on funding and are on their way to improving the clinical processes behind a widespread problem – hearing loss – affecting one in eight Americans over the age of 12.����

“The innovation programs were invaluable in understanding who our customers are, what they needed and how we might get this technology to market,” Neal said. “It’s no good if an idea like this just sits on a shelf. This is a technology that can help people, and it needs to be out in the world to do that.”����

And that’s the goal, Sharon said.����

“We don’t want good ideas to stay on our campus or any campus,” Sharon said. “With these programs, we’re going to keep growing, keep pushing, to move these innovations from lab to market. And with this new MidSouth Hub, I know we can do that on an even bigger scale.”��

are active faculty, scientists and administrators who have demonstrated remarkable innovation producing technologies that have brought, or aspire to bring, real impact on the welfare of society. They also have growing success in patents, licensing and commercialization, while educating and mentoring the next generation of inventors.

“Recognition from NAI is a tremendous accomplishment, and we are extremely proud of these UofL innovators,” said Jon Klein, interim executive vice president for research and innovation. “The research-backed technologies they are developing have the potential to diagnose, treat and cure disease and improve the way we live and work. I look forward to seeing them continue to develop these innovations into practical solutions to real world problems.”

The four inventors selected from UofL, the only ones from Kentucky, are:��

• Thad Druffel, and the . Druffel’s work focuses on solar power, including via his startup, ��which is commercializing a technology meant to make solar power more accessible.��
• Nobuyuki Matoba, . Matoba’s work focuses on tackling devastating diseases, inflammatory bowel disease and cancer, through new vaccines, immunotherapeutics and treatments that leverage protein engineering and plant-based biotechnology.��For his work, Matoba was named UofL’s 2023 Innovator of the Year.��
• Thomas Roussel, Speed School. Roussel focuses on microfabricated/COTS sensor technologies and custom instrumentation, all in support of the development of analytical techniques for environmental studies, orthopedic and rehabilitation platforms, as well as biomedical diagnostic applications.��
• Jagannadh Satyavolu, Speed School and the Conn Center. Satyavolu has a way to leverage spent bourbon stillage to make greener energy solutions and other products, including through his startup, BioProducts LLC.��

UofL and its provide robust support for inventors working to develop and commercialize the technologies emerging from their research, including intellectual property protection, entrepreneurial coaching and product development grants and training. The goal is to translate academic research into products that can save and improve lives.��

In the past fiscal year, UofL was awarded 38 new patents, secured 11 licenses, launched three new startups and brought in a total of $1.4 million in innovation income, including patent royalties and licensing. Over its 25-year history of commercializing research, UofL has been awarded more than 350 U.S. patents, formed nearly 50 startups still in operation and has created countless new products and services positively impacting people here and beyond. For those successes, UofL ranks among the for patents awarded.��

“This year’s class of Senior Members is truly a testament to…what happens when the academic space encourages and celebrates invention and commercialization,” said Paul R. Sanberg, President of NAI. “We are proud to welcome these outstanding academic inventors to the Academy and look forward to supporting and celebrating them as they continue in their innovation journeys.”

UofL researchers can begin their inventor journey , and industry interested in licensing UofL IP can find a full listing of available technologies . ��

The 18-hour event is the university’s largest student-run philanthropy and generates money for and the

The dynamic event, which included themed hours, karaoke and sports tournaments, kicked off Friday at 6 p.m. and ended at noon Saturday with the heartwarming reveal of the total amount raised. As students on stage flipped signs showing the total of $516,485.76, the crowd of students, patients and supporters erupted in a massive celebration.

The funds raised from the 2024 dance marathon brought the cumulative total over the event’s history to more than $5 million.

Read more about this year’s event.

High school students acted as health officials, responding to a simulated infectious disease outbreak public health crisis at the UofL Health Sciences Center on April 15. Event organizers from UofL’s School of Medicine and School of Public Health and Information Sciences and the Kentucky Department for Public Health guided approximately 20 Central High School students through a series of activities to identify the source of a disease outbreak and plan a response.

Presented with a health crisis scenario, the students researched three potential diagnoses, interviewed standardized patients and participated in a “tick drag” to gather insects they suspected to be the source of infections. After determining the outbreak was caused by Rocky Mountain Spotted Fever, the students designed a public health plan to curb the spread.��

The project was a pilot for a larger event to take place June 5 at Morehead State University for 32 students in the Rogers Scholars Program. It is designed to interest the students in health careers.

San Diego, Cal.-based , a biotech firm that offers data, services, insights and tissue for drug developers, has signed a non-exclusive license to use the . The patent-pending UofL technology overcomes a major barrier to drug discovery, allowing researchers more time to test the effectiveness and toxicity of new drugs, drug candidates and gene therapies.

“Limited viability of test heart tissue means there’s less access, which slows down the development of new, potentially life-saving medications,” said Tamer M. A. Mohamed, an associate professor who invented the technology as part of a multi-disciplinary team from the UofL School of Medicine and J.B. Speed School of Engineering. “Our goal is to give researchers more time and speed up the discovery process while improving safety and efficacy.”

Because of the short shelf-life of human heart tissue, many drug candidates today are tested in ways that don’t perfectly emulate living heart tissue or use tests that otherwise don’t show the full range of potential side effects related to cardiotoxicity.��This, Mohamed said, could be a reason some��drug candidates fail Phase 1 clinical trials or get taken off the market after being launched.��

“AnaBios has always believed that a key to successful drug discovery is incorporating human tissue at the preclinical stage,” said Dr. Andre Ghetti, Chief Executive Officer at AnaBios. “We have a long history of implementing human cell-and-tissue-based innovation at industrial scale.��Implementing UofL’s cardiac slice technology is aligned with our translational research focus.”

The technology, protected and licensed through the , extends the tissue’s usable life��to 12 days by mimicking the conditions experienced by a living heart. The tissue ‘lives’ in a pneumatic chamber, receiving��electrical stimulation and nutrition and pumping air instead of blood. AnaBios plans to incorporate these methods into its offerings.��Mohamed co-invented the technology with researcher Guruprasad Giridharan and then doctoral student Moustafa Meki.

“The license and commercialization of this innovative approach are the outcome of the successful collaboration with Dr.��Mohamed and the University of Louisville,”��said Najah Abi-Gerges, AnaBios’s vice president of research and development. “We have been thrilled to contribute to the��validation��of��the cardiac slice technology and believe this UofL research will have a positive impact on medical innovation.”